Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 alone and in combination with antineoplastic agents in participants with relapsed or refractory acute myeloid leukemia and relapsed or refractory and treatment-naive higher risk melodysplastic syndromes.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
• Eastern Cooperative Oncology Group Performance Status of 0 to 2
For Parts A & B:
For Part C:
• Treatment-naïve (TN) (ie, previously untreated) MDS as defined by the 2016 WHO Classification with intermediate, high or very high risk by IPSS-R
For Part D:
• TN AML as defined by the 2016 WHO Classification, including secondary AML and therapy-related AML in participants who are ineligible (IE) for intensive chemotherapy (IC) and allogeneic hematopoietic stem cell transplant (HSCT)
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria apply
Primary purpose
Allocation
Interventional model
Masking
56 participants in 3 patient groups
Loading...
Central trial contact
BMS Study Connect Contact Center http://www.bmsstudyconnect.com/; First line of the email MUST contain the NCT# and Site #.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal